Morgan Stanley analyst Sanjit Singh maintains Elastic (NYSE:ESTC) with a Overweight and raises the price target from $115 to $120.
Lantern Pharma Announces Preclinical Data In Glioblastoma (GBM) With Drug Candidate LP-184 And Expands GBM Research Collaboration
Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company, announced today that a successful preclinical study has shown its drug candidate LP-184 is able to inhibit tumor growth and improve survival in
